Point72 Asset Management
IMNM icon

Point72 Asset Management’s Immunome IMNM Stock Holding History

Point72 Asset Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,000
Closed -$1.61M – 4121
2025
Q4 		$1.61M Buy
+75,000
New +$1.32M ﹤0.01% 2605

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Point72 Asset Management's IMNM Position: Q1 2026 in Review

Point72 Asset Management sold out of Immunome (IMNM) in Q1 2026, closing a stake of 7,034,952 shares — an estimated $151M sold.

Point72 Asset Management first reported a position in IMNM in Q2 2023 and held it in 11 quarters. The position peaked at $151M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Point72 Asset Management reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 7,034,952 Immunome shares in Q1 2026, an estimated $151M.
  • Point72 Asset Management first reported a position in Immunome in Q2 2023 and held it in 11 quarters.
  • Point72 Asset Management's Immunome position peaked at $151M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.